Canadian Respiratory Journal

Canadian Respiratory Journal / 2005 / Article

Original Article | Open Access

Volume 12 |Article ID 612387 | https://doi.org/10.1155/2005/612387

Van Hung Nguyen, Serge Péloquin, Yves Lacasse, "Cost Effectiveness of Positron Emission Tomography for the Management of Potentially Operable Non-Small Cell Lung Cancer in Quebec", Canadian Respiratory Journal, vol. 12, Article ID 612387, 7 pages, 2005. https://doi.org/10.1155/2005/612387

Cost Effectiveness of Positron Emission Tomography for the Management of Potentially Operable Non-Small Cell Lung Cancer in Quebec

Abstract

BACKGROUND: The potential benefits of positron emission tomography (PET) scanning stem from the fact that it can reduce the number of diagnostic examinations; particularly, the number of unnecessary thoracic surgeries.OBJECTIVE: To evaluate the economic impact and cost-effectiveness of PET scanning in the management of potentially operable non-small cell lung cancer in Quebec.METHODS: A decision tree was developed. Two strategies were compared: chest computed tomography (CT) alone or CT and whole-body PET. The various paths of each strategy were dependent on the numerous variables that were determined from a literature review. The costs and life expectancy were determined for each strategy under consideration. Life expectancy was calculated using the declining exponential approximation of life expectancy. Costs were obtained from the Quebec diagnosis-related group database and Quebec physician fee schedules.RESULTS: The mean cost of the CT strategy was $8,455 per patient compared with $9,723 for the PET strategy, for a cost differential of $1,268. The PET strategy extended life expectancy by slightly more than three months (0.27 years) compared with the survival of the CT strategy. The incremental cost-effectiveness ratio was $4,689. Considering the number of new cases and the prevalence of mediastinal metastases, the budget impact would be $8,613,693.CONCLUSION: The use of PET to detect local and distant metastases in non-small cell lung cancer is an intervention that would require an acceptable investment for each life-year gained.

Copyright © 2005 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views47
Downloads271
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.